Osmosis Investment Management UK Ltd Purchases New Shares in Revolution Medicines, Inc. $RVMD

Osmosis Investment Management UK Ltd purchased a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,447 shares of the company’s stock, valued at approximately $646,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Contravisory Investment Management Inc. purchased a new stake in shares of Revolution Medicines in the second quarter valued at $32,000. Global Retirement Partners LLC boosted its position in shares of Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after buying an additional 361 shares during the period. Torren Management LLC purchased a new position in shares of Revolution Medicines during the fourth quarter valued at approximately $33,000. Johnson Financial Group Inc. bought a new position in shares of Revolution Medicines during the second quarter valued at approximately $37,000. Finally, Arax Advisory Partners bought a new position in shares of Revolution Medicines during the fourth quarter valued at approximately $38,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, Director Sushil Patel sold 5,580 shares of Revolution Medicines stock in a transaction on Monday, June 29th. The stock was sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the completion of the sale, the director directly owned 21,656 shares of the company’s stock, valued at $4,071,111.44. The trade was a 20.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total value of $3,366,600.00. Following the sale, the chief financial officer directly owned 123,269 shares of the company’s stock, valued at approximately $20,749,870.77. This trade represents a 13.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 212,497 shares of company stock worth $38,206,486 over the last three months. Corporate insiders own 7.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on RVMD shares. Oppenheimer reissued an “outperform” rating and set a $230.00 price target on shares of Revolution Medicines in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research report on Friday, July 17th. Guggenheim increased their target price on Revolution Medicines from $235.00 to $240.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Evercore reiterated an “outperform” rating and set a $230.00 target price on shares of Revolution Medicines in a research report on Thursday, August 6th. Finally, Royal Bank Of Canada boosted their target price on shares of Revolution Medicines from $182.00 to $203.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $167.89.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD opened at $211.38 on Wednesday. The firm has a market cap of $45.31 billion, a PE ratio of -23.97 and a beta of 1.39. The firm’s 50 day simple moving average is $190.11 and its 200-day simple moving average is $146.46. Revolution Medicines, Inc. has a one year low of $35.62 and a one year high of $220.34. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the previous year, the company earned ($1.31) EPS. As a group, equities analysts predict that Revolution Medicines, Inc. will post -8.82 EPS for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.